Pharmalittle: CVS-Glenview meeting, Dupixent approval

Good morning, everybody, and welcome to a different working week. We hope the weekend respite was enjoyable and invigorating, as a result of that oh-so acquainted routine of deadlines, on-line conferences and telephone calls has predictably returned. However what are you able to do? The world, reminiscent of it’s, continues to spin. So time to offer it a nudge in a greater route by brewing cups of stimulation. Our alternative in the present day is maple bourbon, a double shot for the needy neurons. In the meantime, listed below are a number of objects of curiosity to start out you in your journey, which we hope is significant and productive. Better of luck and do be in contact…

A serious hedge-fund investor will meet prime CVS Well being executives in the present day to suggest methods the struggling well being care firm can enhance its operations, the potential begin of an activist stance by the fund, The Wall Road Journal reviews. The slated assembly, between CVS and hedge fund Glenview Capital Administration, comes amid indicators traders are turning stressed with an organization that is still among the many best-recognized within the healthcare trade however has seen its inventory tumble 24% this yr up to now. Larry Robbins, founding father of well being care-focused Glenview, has established a big place in CVS and is predicted to satisfy with CVS chief govt officer Karen Lynch and others to current methods to energise the corporate, however to not push for a break up.

The U.S. Well being Assets and Providers Administration despatched a closing warning letter to Johnson & Johnson urging the corporate to tell the company by in the present day that it might halt its plan to change fee strategies for some hospitals that take part within the 340B drug low cost program. J&J just lately disclosed plans to situation rebates for 2 broadly prescribed medicines beginning Oct. 15 as a substitute of providing discounted costs, however the HRSA warned the transfer would violate federal regulation. HRSA argued the deliberate transfer is illegal as a result of it might require the hospitals to buy the medicines at costs exceeding what the low cost program permits. The company additionally insisted the transfer requires approval by the U.S. Division of Well being and Human Providers, which oversees the company. In consequence, the HRSA warned J&J that its contract with HHS to take part within the 340B program may very well be terminated and that the corporate faces penalties that will price $7,000 for every violation.